US › Healthcare

Erasca Inc (ERAS)

US · Healthcare · Biotechnology

$18.38+3.03%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-183.4M

Profit YoY

-492.4%

EPS

$-0.60

EPS estimate

$-0.23

EPS came in at -0.60 against a street estimate of -0.23 — a miss of 160.9%.

Key statistics

Market cap

$6.30B

Forward P/E

0.0

P/B

16.01

Book value

$1.27

EPS (TTM)

$-0.93

52-week high

$24.28

52-week low

$1.33

50-day MA

$15.99

200-day MA

$10.91

Beta

0.67

Analyst view

Analysts rate Erasca Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $22.80.

Shareholding

Insiders

9.69%

Institutions

85.34%

Largest institutional holders

Fund	Stake
Frazier Life Sciences Management, L.P.	8.68%
T. Rowe Price Investment Management,Inc.	7.48%
BlackRock Inc	7.09%
VR Adviser, LLC	5.77%
RTW INVESTMENTS, LLC	5.69%
Vanguard Group Inc	4.51%
Vivo Capital, LLC	4.28%
Vanguard Capital Management, LLC	3.96%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Erasca Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.